Drugs / \[68Ga\]DOTA-IR-780-C-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07162779 | Oct 2024 → Dec 2026 expected | — | Affiliated Hospital of Jiangnan University | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[68Ga\]DOTA-IR-780-C-4 | “\[68Ga\]DOTA-IR-780-C-4 is administered through a superficial vein on the back of the hand.” NCT07162779 ↗ |
| Route | Intravenous | “administered through intravenous injection” NCT07162779 ↗ |